Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05947851 · ClinicalTrials.gov registry record · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
A Phase 3 study of Leukemia, Lymphocytic, Chronic, B-Cell and CLL, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 735
- Enrollment target
- 20
- Study locations
NCT05947851 is a Phase 3 study of Leukemia, Lymphocytic, Chronic, B-Cell and CLL that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 735 participants, above the 424-participant average among 11 other Leukemia, Lymphocytic, Chronic, B-Cell trials with a reported enrollment target (73% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT05947851, a Phase 3 study of Leukemia, Lymphocytic, Chronic, B-Cell and CLL, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 735 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Nemtabrutinib
- BIOLOGICAL Rituximab
Study Locations (20)
Other
- Centro Medico Fleischer ( Site 1006) - Buenos Aires
- Hospital Aleman-oncohematologic diseases ( Site 1001) - Buenos Aires
- ZAS Cadix ( Site 1203) - Antwerp
- ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308) - São Paulo
Buenos Aires
- Instituto Alexander Fleming ( Site 1005) - Ciudad Autónoma de Buenos Aires
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 1007) - Mar del Plata
Region M. de Santiago
- Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1509) - Santiago
- FALP-UIDO ( Site 1500) - Santiago
Arkansas
- Highlands Oncology Group ( Site 5405) - Springdale
California
- MemorialCare Health System - Long Beach Medical Center ( Site 5421) - Long Beach
Florida
- Memorial Hospital West ( Site 5410) - Pembroke Pines
Oregon
- Oregon Health and Science University ( Site 5425) - Portland
Washington
- Medical Oncology Associates, PS ( Site 5406) - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 735 participants |
| Start Date | 2023-08-08 |
| Est. Completion | 2035-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05947851
The ClinicalTrials.gov registry entry for NCT05947851 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 735 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 424-participant average among 11 other Leukemia, Lymphocytic, Chronic, B-Cell trials with a reported enrollment target (73% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Leukemia, Lymphocytic, Chronic, B-Cell appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT05947851 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Buenos Aires, Region M. de Santiago.
Frequently Asked Questions
What is clinical trial NCT05947851 about?
NCT05947851 is a clinical study titled "A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).". The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progre...
What is the current status of trial NCT05947851?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 735 participants. The study started on 2023-08-08. Estimated completion is 2035-07-01.
What conditions does trial NCT05947851 study?
This clinical trial studies the following conditions: Leukemia, Lymphocytic, Chronic, B-Cell, CLL, SLL, Lymphoma, Small Lymphocytic, Leukemia, Chronic Lymphocytic.
What interventions are being tested in trial NCT05947851?
The interventions under investigation include: Venetoclax (DRUG), Nemtabrutinib (DRUG), Rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05947851?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05947851 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Lymphocytic, Chronic, B-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
ACTIVE NOT RECRUITING · Phase 3
-
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
RECRUITING · Phase 1
-
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
RECRUITING · Phase 1
-
Family Study of Lymphoproliferative Disorders
RECRUITING
-
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
-
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.